ArticleBMC medicine2022
Modelling upper respiratory viral load dynamics of SARS-CoV-2.
Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19.British journal of clinical pharmacology · 2026Trial
- Efficacy of three antimicrobial mouthwashes in reducing SARS-CoV-2 viral load in the saliva of hospitalized patients: a randomized controlled pilot study.Scientific reports · 2023Trial
- Lateral flow test performance in children for SARS-CoV-2 using anterior nasal and buccal swabbing: sensitivity, specificity, negative and positive predictive values.Archives of disease in childhood · 2023Trial
- Species-specific barriers restrict virus spillover potential across the Caenorhabditis genus.PLoS biology · 2026Article
- The Role of Viral Load in COVID-19-Induced Encephalitis.Journal of clinical medicine · 2026Article
- Informing optimal testing and isolation strategies across different stages of the diagnostic development pipeline using mathematical models: SARS-CoV-2 in the UK as a case study.BMJ public health · 2026Article
- A five-domain functional framework for integrative physiology: a coherent and operational approach to whole-body function.Frontiers in physiology · 2026Review
- Random time-shift approximation enables hierarchical Bayesian inference of mechanistic within-host viral dynamics models on large datasets.PLoS computational biology · 2025Article
- Temporal Dynamics of SARS-CoV-2 Detection in Household Contacts: Divergences Between Time to First Positive Test, Symptom Onset, and Maximum Viral Load.Infectious diseases and therapy · 2025Article
- Article
- SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study.Nature communications · 2025Article
- A biomathematical model of SARS-CoV-2 in Syrian hamsters.Scientific reports · 2024Article
- Article
- The kinetics of SARS-CoV-2 infection based on a human challenge study.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Within-host dynamics of antiviral treatment with remdesivir for SARS-CoV-2 infection.Journal of the Royal Society, Interface · 2024Article
- Recent approaches in computational modelling for controlling pathogen threats.Life science alliance · 2024Review
- Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.The Journal of infectious diseases · 2024Article
- SARS-CoV-2 PCR cycle threshold value at admission might not be a good predictor of in-hospital COVID-19-associated AKI.Journal of general and family medicine · 2024Article
- Symptom propagation in respiratory pathogens of public health concern: a review of the evidence.Journal of the Royal Society, Interface · 2024Review
- Differences in virus and immune dynamics for SARS-CoV-2 Delta and Omicron infections by age and vaccination histories.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Relationships between viral load, severity of illness, and transmissibility of virus are fundamental to understanding pathogenesis and devising better therapeutic and prevention strategies for COVID-19. Here we present within-host modelling of viral load dynamics observed in the upper respiratory tract (URT), drawing upon 2172 serial measurements from 605 subjects, collected from 17 different studies. We developed a mechanistic model to describe viral load dynamics and host response and contrast this with simpler mixed-effects regression analysis of peak viral load and its subsequent decline. We observed wide variation in URT viral load between individuals, over 5 orders of magnitude, at any given point in time since symptom onset. This variation was not explained by age, sex, or severity of illness, and these variables were not associated with the modelled early or late phases of immune-mediated control of viral load. We explored the application of the mechanistic model to identify measured immune responses associated with the control of the viral load. Neutralising antibodies correlated strongly with modelled immune-mediated control of viral load amongst subjects who produced neutralising antibodies. Our models can be used to identify host and viral factors which control URT viral load dynamics, informing future treatment and transmission blocking interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.